The development of a non-invasive fetal ECG technology that can detect and display fetal ECG signals as early as 12 weeks into the pregnancy is a significant breakthrough in both the scientific and business fields. The technology continues a line of successful products developed by the same team, namely WIWE a handheld rest ECG device, Heartbit a wearable stress ECG kit, and Dualscope, a 2-headed digital stethoscope and ECG device.
- Early Detection of Fetal Abnormalities: The early detection of fetal ECG signals can help in identifying potential fetal abnormalities and complications much earlier than current methods, which could lead to better management of high-risk pregnancies.
- Better Understanding of Fetal Development: The fetal ECG signals provide valuable insights into fetal cardiac function and development, which can aid in better understanding of fetal physiology and development.
- Reduced Risk of Invasive Procedures: The non-invasive nature of this technology reduces the need for invasive procedures such as amniocentesis or chorionic villus sampling, which are associated with an increased risk of complications.
- Improved Management of Complications: The ability to monitor fetal ECG signals non-invasively can aid in the management of complications such as fetal distress and premature labor, leading to better outcomes for both the mother and the baby.
- Improved Accuracy in Fetal Monitoring: The fetal ECG technology can provide a more accurate and detailed picture of fetal cardiac function and development, which can aid in the diagnosis and management of complications such as fetal distress and premature labor.
- Improved Patient Experience: The non-invasive nature of the fetal ECG technology improves the patient experience by reducing the discomfort and risk associated with invasive procedures, and by allowing for more continuous and convenient monitoring of fetal health.
- Improved Outcomes for Mothers and Babies: The improved accuracy and earlier detection of fetal abnormalities provided by the fetal ECG technology can lead to improved outcomes for both the mother and the baby, including a reduction in maternal and neonatal morbidity and mortality.
- Increased Market Potential: The ability to monitor fetal ECG signals non-invasively is a significant improvement in the field of fetal monitoring, and has the potential to capture a significant market share in the fetal monitoring industry.
- Competitive Advantage: Companies that possess this technology would have a significant competitive advantage over existing fetal monitoring technologies.
- Potential for New Revenue Streams: The development of this technology opens up new revenue streams for companies that specialize in fetal monitoring and related fields.
- Improved Patient Outcomes: The improved monitoring capabilities provided by this technology can lead to better patient outcomes, which in turn can increase patient satisfaction and loyalty.
A company that gathers new data using Axalton’s non-invasive fetal ECG technology can generate revenues by selling the data to various entities that have an interest in fetal health and development. Some potential buyers of this big data of fetal ECG include:
- Healthcare Providers: Healthcare providers such as hospitals, clinics, and obstetricians are interested in purchasing fetal ECG data to aid in the diagnosis and management of high-risk pregnancies.
- Pharmaceutical Companies: Pharmaceutical companies are interested in purchasing fetal ECG data to aid in the development of drugs and therapies for fetal and neonatal health.
- Research Institutions: Research institutions are interested in purchasing fetal ECG data to conduct further studies on fetal physiology and development.
- Health Insurers: Health insurers are interested in purchasing fetal ECG data to better understand fetal health risks and to develop new insurance products and policies for pregnant women.
- Government Agencies: Government agencies are interested in purchasing fetal ECG data to aid in the development of public health policies and programs related to maternal and fetal health.
Axalton enables its customers using this technology to generate revenues from selling the big data of fetal ECG through various means such as licensing agreements, data-sharing partnerships, and customized reports. Customers can also offer value-added services such as data analytics and consulting to further monetize the data. The sale and use of healthcare data are regulated by various laws, such as HIPAA in the United States. Companies must ensure that they comply with these laws and maintain patient privacy and confidentiality.